Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Evinacumab · 1 trial · 1 indication
Change in total cholesterol, LDL-Cholesterol, HDL-Cholesterol, triglyceride, non-HDL-Cholesterol and apolipoprotein B plasma concentration
| Arm | Type | Description |
|---|---|---|
| Evinacumab-treated patients | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Evinacumab | DRUG | Evinacumab 15 mg/kg administered intravenously every 4 weeks |
Inclusion Criteria: * HoFH patients having been previously or being currently treated with evinacumab or clinical diagnosis of HoFH requiring additional lipid lowering therapy. Exclusion Criteria: * Any new condition or worsening of an existing condition, which in the opinion of the investigator ...
Evinacumab is used for the treatment of homozygous familial hypercholesterolemia, a genetic condition characterized by extremely high levels of low-density lipoprotein cholesterol. It is being developed by Ultragenyx Pharmaceutical Inc. (ticker: RARE) and is currently in Phase 3 clinical development.
Evinacumab is being developed by Ultragenyx Pharmaceutical Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol RARE. The company is conducting clinical trials to evaluate the drug's safety and effectiveness for the treatment of homozygous familial hypercholesterolemia.
Evinacumab is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. A Phase 3 clinical trial has been completed to assess its safety and effectiveness in patients with homozygous familial hypercholesterolemia.
Evinacumab has been studied in a completed Phase 3 clinical trial with the identifier NCT05611528. This trial, titled 'Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia,' enrolled 10 participants in Canada and was not randomized or double-blinded.
Evinacumab is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for the treatment of homozygous familial hypercholesterolemia. The completed Phase 3 trial, NCT05611528, has finished, but the drug remains under investigation and has not received regulatory approval.